{
    "nct_id": "NCT06121843",
    "official_title": "A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component",
    "inclusion_criteria": "* History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)\n* Measurable multiple myeloma (MM)\n* Eastern Cooperative Oncology Group performance status of 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Condition that confounds the ability to interpret data from the study\n* Known active or history of central nervous system (CNS) involvement of MM\n\nNote: Other protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}